Abstract:Background This study aimed to comprehensively explore the clinical significance of PIK3CA mutation in human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with anti-HER2 therapy. Methods We systematically searched PubMed, Embase, and the Cochrane databases for eligible studies assessing the association between PIK3CA mutation and outcomes in patients with HER2-positive breast cancer receiving anti-HER2 therapy. The main outcomes included: (1) pathological complete response (pCR) or disease-free survival (DFS) for the neoadjuvant setting; (2) DFS or invasive DFS for the adjuvant setting; (3) objective response rate (ORR), progression-free survival (PFS), time-to-progression (TTP), or overall survival (OS) for the metastatic setting. The mutational landscape of HER2-positive breast cancer according to PIK3CA mutation status was examined based on TCGA breast cancer dataset. Results Totally, 43 eligible studies, covering 11,099 patients with available data on PIK3CA mutation status, were identified. In the neoadjuvant setting, PIK3CA mutation was significantly associated with a lower pCR rate (OR=0.23, 95% CI 0.19–0.27, p <0.001). This association remained significant irrespective of the type of anti-HER2 therapy (single-agent or dual-agent) and hormone receptor status. There were no significant differences in DFS between PIK3CA mutated and wild-type patients in either the neoadjuvant or adjuvant settings. In the metastatic setting, PIK3CA mutation predicted worse ORR (OR=0.26, 95%CI 0.17–0.40, p <0.001), PFS (HR=1.28, 95%CI 1.03–1.59, p = 0.024) and TTP (HR=2.27, 95%CI 1.54–3.34, p <0.001). However, no significant association was observed between PIK3CA mutation status and OS. Distinct mutational landscapes were observed in HER2-positive breast cancer between individuals with PIK3CA mutations and those with wild-type PIK3CA . Conclusions PIK3CA mutation was significantly associated with a lower pCR rate in HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy. In the metastatic setting, PIK3CA mutation was predictive of worse ORR, PFS and TTP. These results suggest the potential for developing PI3K inhibitors as a therapeutic option for these patients.

Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer.

Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer

Pik3ca Mutation Analysis in Chinese Patients with Solid Tumors.

Occurrence of Low Frequency PIK3CA and AKT2 Mutations in Gastric Cancer.

Clinicopathological Characteristics and Prognostic Analysis of PIK3CA Mutation in Breast Cancer Patients in Northwest China

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‐BRCA data

Expression, Characteristics, and Clinical Target Prediction of PIK3C3/ vps34 in Gastric Cancer

Frequency, Characterization, and Prognostic Analysis of PIK3CA Gene Mutations in Chinese Esophageal Squamous Cell Carcinoma.

The Relationship Between Gene Mutations and the Clinicopathological Features and Prognosis of Gastric Cancer.

PIK3CA Mutations Define Favorable Prognostic Biomarkers in Operable Breast Cancer: a Systematic Review and Meta-Analysis

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.

Prevalence and characteristics of PIK3CA mutation in mismatch repair-deficient colorectal cancer.

PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients

Plasma PIK 3 CA Ctdna Specific Mutation Detected by Next Generation Sequencing is Associated with Clinical Outcome in Advanced Breast Cancer

PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer

KRAS and PIK3CA Bi-Mutations Predict a Poor Prognosis in Colorectal Cancer Patients: A Single-Site Report.

The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients

Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population.

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis